-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $30

Benzinga·03/02/2026 13:59:36
Listen to the news
Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $47 to $30.